Table 3.
Sensitivity analysis for risk factors related to ovarian metastasis
| SCC |
Adeno/AS |
Age < 50 |
Clinical stage IB |
|||||
|---|---|---|---|---|---|---|---|---|
| (%)† | OR (95%CI) | (%)† | OR (95%CI) | (%)† | OR (95%CI) | (%)† | OR (95%CI) | |
| Histology | ||||||||
| SCC | 0.6% | 1 | 0.7% | 1 | ||||
| Adeno | 2.0% | 5.54 (2.46–12.5)* | 2.5% | 2.70 (1.25–5.84)** | ||||
| AS | 0.6% | 0.84 (0.17–4.02) | 1.3% | 0.65 (0.08–5.06) | ||||
| Others | 0.0% | na | 1.4% | na | ||||
| Parametrea | ||||||||
| Not involved | 0.9% | 1 | 0.5% | 1 | ||||
| Involved | 8.7% | 3.40 (1.67–6.93)* | 3.5% | 2.33 (1.01–5.36)** | ||||
| Uterine corpus | ||||||||
| Not involved | 0.4% | 1 | 0.8% | 1 | 0.5% | 1 | 0.5% | 1 |
| Involved | 3.3% | 5.55 (2.50–12.3)* | 9.4% | 6.50 (3.19–13.2)* | 5.0% | 4.58 (2.10–9.96)* | 5.7% | 8.49 (3.91–18.4)* |
| Pelvic lymph node | ||||||||
| Not involved | 0.2% | 1 | 0.9% | 1 | 0.3% | 1 | 0.4% | 1 |
| Involved | 2.2% | 6.09 (2.17–17.3)* | 6.7% | 3.91 (1.93–7.93)* | 3.0% | 6.10 (2.38–15.6)* | 3.5% | 6.64 (2.91–15.1)* |
| Para-aortic lymph node | ||||||||
| Not involved | 0.6% | 1 | 0.7% | 1 | ||||
| Involved | 11.0% | 6.78 (1.67–27.6)* | 11.7% | 7.42 (1.68–32.9) | ||||
| Clinically not involved | 0.5% | 0.85 (0.25–2.98) | 0.8% | 1.44 (0.41–5.04) | ||||
| Hosmer and Lemeshow test | p = 0.41 | p = 0.36 | p = 0.78 | p = 0.22 | ||||
Binary logistic regression models (conditional backward) for multivariable analysis (*p < 0.01, **p < 0.05). All the collected covariates were initially entered in the model, and only the statistically significant covariates (cutoff, p < 0.05) were listed in the table. Adjusted-odds ratio with 95% confidence interval are shown.
†
Ovarian metastasis based on risk factor.
Abbreviations: SCC: squamous cell carcinoma; Adeno: adenocarcinoma; AS: adenosquamous.